Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I trial of WP1732 for treatment of pancreatic cancer

Trial Profile

A Phase I trial of WP1732 for treatment of pancreatic cancer

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2018

At a glance

  • Drugs WP 1732 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Moleculin Biotech
  • Most Recent Events

    • 01 Dec 2018 New trial record
    • 28 Nov 2018 According to a Moleculin Biotech media release, an Investigational New Drug (IND) application with the FDA is expected to file in 2019.
    • 15 Nov 2018 According to a Moleculin Biotech media release, the company is planning a Pre-Investigational New Drug (IND) Meeting to finalize IND filling to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top